MyFinsight
Home
Blog
About
Short-term investments
$350,251K
(202.61%↑ Y/Y)
Cash and cash
equivalents
$175,677K
(-8.52%↓ Y/Y)
Inventory
$70,930K
(47.22%↑ Y/Y)
Prepaid expenses and
other current assets
$48,285K
(48.85%↑ Y/Y)
Accounts receivable, net
$23,490K
(-26.39%↓ Y/Y)
Total current assets
$668,633K
(59.08%↑ Y/Y)
Deferred tax assets
$190,965K
(-7.08%↓ Y/Y)
Intangible asset, net
$14,750K
(-6.35%↓ Y/Y)
Other long-term
assets
$10,834K
(32.20%↑ Y/Y)
Operating lease
right-of-use assets
$8,353K
(-18.93%↓ Y/Y)
Property and equipment,
net
$2,575K
(139.31%↑ Y/Y)
Total assets
$896,110K
(35.54%↑ Y/Y)
Total liabilities and
shareholders' equity
$896,110K
(35.54%↑ Y/Y)
Total shareholders'
equity
$654,149K
(32.15%↑ Y/Y)
Total liabilities
$241,961K
(45.63%↑ Y/Y)
Accumulated deficit
-$414,114K
(16.30%↑ Y/Y)
Accumulated other
comprehensive loss
-$1,380K
(-2503.77%↓ Y/Y)
Additional paid-in capital
$1,069,622K
(8.06%↑ Y/Y)
Total current
liabilities
$171,247K
(45.34%↑ Y/Y)
Other long-term
liabilities
$34,018K
(267.29%↑ Y/Y)
Non-current deferred
revenue
$31,811K
(0.00%↑ Y/Y)
Non-current operating lease
liabilities
$4,885K
(-32.56%↓ Y/Y)
Ordinary shares
value-Common Class A
$12K
(0.00%↑ Y/Y)
Ordinary shares
value-Common Class B1
$4K
(0.00%↑ Y/Y)
Ordinary shares
value-Common Class A1
$4K
(0.00%↑ Y/Y)
Ordinary shares
value-Common Class B
$1K
(0.00%↑ Y/Y)
Accrued collaboration
expenses
$88,049K
(68.07%↑ Y/Y)
Accrued expenses
$46,730K
(29.95%↑ Y/Y)
Other current
liabilities
$20,052K
(11.39%↑ Y/Y)
Accounts payable
$12,404K
(38.50%↑ Y/Y)
Operating lease
liabilities
$4,012K
(59.08%↑ Y/Y)
Back
Back
Balance Sheet
Kiniksa Pharmaceuticals International, plc (KNSA)
Kiniksa Pharmaceuticals International, plc (KNSA)
source: myfinsight.com